

QRxPharma October 2011



MoxDuo®

**Better pain relief,
Fewer side effects**

Chris Campbell - CFO

DISCLAIMER

This presentation, including information contained in this disclaimer, is given to you in strict confidence. By attending the presentation, you agree that no part of this presentation or disclaimer may be disclosed, distributed or reproduced to any third party without the consent of QRxPharma Limited ("QRxPharma").

This presentation is being provided for the sole purpose of providing the recipients with background information about QRxPharma's business. This presentation, including the information contained in this disclaimer, does not constitute an offer, invitation or recommendation to subscribe for or purchase any security and neither the presentation, disclaimer nor anything contained in them forms the basis of any contract or commitment. This presentation does not purport to summarize all information that an investor should consider when making an investment decision. It should be read in conjunction with QRxPharma's other continuous disclosure announcements lodged with the ASX which are available at www.asx.com.au. Before making an investment decision you should consider whether it is suitable for you in light of your own investment profile and objectives and financial circumstances and the merits and risk involved.

No representation, express or implied, is made as to the fairness, accuracy, completeness or correctness of information, opinions and conclusions contained in this presentation, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in the presentation ("forward-looking statements"). Such forward-looking statements are by their nature subject to significant uncertainties and contingencies and are based on a number of estimates and assumptions that are subject to change (and in many cases are outside the control of QRxPharma and its Directors) which may cause the actual results or performance of QRxPharma to be materially different from any future results or performance expressed or implied by such forward-looking statements. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

To the maximum extent permitted by law, neither QRxPharma nor its related corporations, directors, employees or agents, nor any other person, accepts any liability, including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it.

You represent and confirm by attending and/or retaining this presentation, that you accept the above conditions.

COMPANY OVERVIEW

- **New Drug Application** filed with FDA for MoxDuo IR
- **FDA approval expected to take 10 to 12 months**
- **Multi-Billion dollar global market: \$US14bn¹**
- **Opens therapeutic window for pain relief**
- **Global IP strength: patent exclusivity through 2029**
- **Strategic partnerships: partnering deal in CY2011**
- **MoxDuo sales revenues expected in CY2012**

OPPORTUNITY SNAPSHOT

- **Blockbuster potential in a growing market**
 - In the US: IR \$2.0bn; IV \$274mm; CR \$5.6bn ¹
 - Subject to FDA approval, MoxDuo IR ready to launch in CY2012
- **MoxDuo key advantages**
 - Widen therapeutic window for acute pain relief
 - Equal or better pain relief with fewer side effects than morphine, oxycodone and Percocet®
 - **Possible breakthrough benefits with less risk of opioid-induced respiratory failure**
- **Economic impact to healthcare system**
 - Speedier recoveries = fewer days in hospital
 - KOL and payor acceptance of value/clinical benefits
- **Strong patent protection**
 - Composition of matter, therapeutic use, Method of Administration, and new formulations

MoxDuo IR – Better pain relief, fewer and less severe side effects

FORMULATIONS: FROM HOSPITAL TO HOME

- **MoxDuo IR** (Immediate Release): oral capsules
 - Target: Moderate to severe acute pain
 - Status: Phase 3 registration program completed
 - **NDA filed in July, 2011**
- **MoxDuo CR** (Controlled Release): oral tablet with abuse deterrent technology
 - Target: Chronic pain (i.e. osteoarthritis, back, neuropathic)
 - Status: Phase 1
- **MoxDuo IV** (Intravenous): liquid formulation
 - Target: Hospital-based moderate to severe pain
 - Status: Phase 2; concurrent formulation development

MOXDuo IR US PEAK SALES POTENTIAL

- Over 210 mm Rx for acute pain drugs in US/year
- QRxPharma conservatively targets MoxDuo for 2.5% of these Rxs by 2015
- Priced at \$2/capsule, 4X day, 14 days = \$112/Rx
- Peak sales of +\$600 mm by 2015
- Managed care and reimbursers endorse price
- Further advantaged by changing acute pain market
 - Vicodin will lose about 100 mm prescriptions due to paracetamol and rescheduling
 - Could lead to MoxDuo sales in excess of \$2 b/year

MoxDuo IR and MoxDuo CR have blockbuster market potential

VALUE DRIVERS: NEAR TERM MILESTONES

- ✓ MoxDuo IR Phase 3 total knee replacement trial Q1, 2011
- ✓ MoxDuo IR Pre-NDA meeting with FDA end Q1, 2011
- ✓ MoxDuo IR adverse events study results Q2, 2011
- ✓ MoxDuo IR NDA submission July 2011
- ☐ Strategic partnership 2011
- ☐ Complete two Phase 1 trials for MoxDuo CR by Q1, 2012
- ☐ Implement plan to bring MoxDuo IR to market in 2012
- ☐ Submit Marketing Authorisation Application (MAA) in Europe for MoxDuo IR mid year 2012

FINANCIAL SUMMARY (18 OCT 2011)

Shares on issue:	144 million (ordinary)
Market cap:	A\$210 million
Cash on hand:	
30 June 2011	A\$ 7.3 million
Net proceeds from raising ¹	A\$25.1 million
Proforma cash on hand	A\$32.4 million
Cash burn:	FY2013
Share registry:	+80% institutional / HNW
Listing:	ASX: QRX / OTCQX: QRXPY

¹ Proceeds of July 2011 Placement and Rights Issue after expenses of the capital raising



“The clinical advantages of MoxDuo IR have the potential to change the traditional methods of treating moderate to severe pain by providing **better pain relief without many of the debilitating side effects** seen with traditional opioid drugs.”

Please join us for a
Breakfast Symposium entitled:

**Dual-Opioid™ Therapy:
Changing the Paradigm**

Tuesday, August 31, 2010
7:00 AM – 8:00 AM

Palais des Congrès de Montréal
201, Viger Street West
Room 513 ABCD
Montréal (QC) Canada H2Z 1X7

HOLD IN CONJUNCTION WITH THE
MONTREAL 2010 13th WORLD
CONGRESS ON PAIN™

A graphic of a molecular structure with yellow spheres and white rods, featuring circular insets showing a green hand holding a syringe, a brain, and a green sphere with yellow dots.

Dr. Bruce Nicholson, leading US pain physician